Skip to Main Content

Business

November 2, 2009
Volume 87, Number 44
Web Exclusive

Hikal Branches Out

Indian fine chemicals manufacturer sets up contract research arm

Rick Mullin

GETTING STARTED: Acoris addes early-stage hit-to-lead research and kilogram-scale manufacturing to Hikal's contract manufacturing business. Acoris
GETTING STARTED Acoris adds early-stage hit-to-lead research and kilogram-scale manufacturing to Hikal's contract manufacturing business.
  • Print this article
  • Email the editor

More Business Stories

October 24, 2011

Celanese Takes An Ethanol Plunge (Member Content)

(October 24, 2011 | Vol. 89 Issue 43 | pp. 20-21)

The chemical producer seeks to make ethanol a major business but is secretive about details of its process.

Building On The Momentum (Member Content)

(October 24, 2011 | Vol. 89 Issue 43 | p. 22)

BWA Water Additives rides crest of rising demand for specialty water treatment chemicals.

European Firms Invest In China

(October 24, 2011 | Vol. 89 Issue 43 | p. 6)

Specialty Chemicals: Companies pursue local research and production.

Investors Bet On Cleantech

(October 24, 2011 | Vol. 89 Issue 43 | p. 9)

Green Chemistry: Close to $1 billion is slated for start-up firms.

Business Concentrates (Member Content)

(October 24, 2011 | Vol. 89 Issue 43 | p. 18)

 

October 17, 2011

Emerging Strategies

(October 17, 2011 | Vol. 89 Issue 42 | pp. 15-26)

Faced with change, pharmaceutical firms shift business mix to generics and emerging markets.

A Sense of Urgency (Member Content)

(October 17, 2011 | Vol. 89 Issue 42 | pp. 30-32)

Call for drug safety pushes the mundane art of supply chain management to the front burner.

Growing Businesses The Scottish Way (Member Content)

(October 17, 2011 | Vol. 89 Issue 42 | pp. 33-35)

Development authorities seek to harness industry‑academia cooperation in the life sciences.

An Update On Dow (Member Content)

(October 17, 2011 | Vol. 89 Issue 42 | pp. 36-38)

CEO Andrew N. Liveris believes the major pieces are in place to continue the company's transformation.

AstraZeneca Shifts Operations

(October 17, 2011 | Vol. 89 Issue 42 | p. 10)

Pharmaceuticals: Firm will add manufacturing in China while cutting jobs in the U.S.

Investment Deterrent

(October 17, 2011 | Vol. 89 Issue 42 | p. 11)

Venture capital firms say FDA regulations hamper their support of biopharma companies.

Business Concentrates (Member Content)

(October 17, 2011 | Vol. 89 Issue 42 | pp. 28-30)

 

Text Size A A

Despite worries over supply-chain security after incidents of contaminated drugs from Asia last year, most major pharmaceutical companies insist that proven players in India and China will remain a fixture in their active pharmaceutical ingredient (API)-outsourcing strategies. Indian suppliers are particularly well established in the sector, and many had a large presence at CPhI, the pharmaceutical ingredients conference, in Madrid last month.

In fact, the field has become competitive, with firms such as Piramal Healthcare taking positions among the top global contract manufacturers. As in the U.S. and Europe, companies in India are jockeying to offer what they perceive as an ideal spread of services along the drug development continuum from discovery to commercialization.

Hikal, a contract fine chemicals firm with headquarters in Mumbai, is responding to the competition by expanding its services into contract research and kilogram-scale manufacturing, according to Anish Swadi, vice president of business development.

Last year, Hikal launched an independent subsidiary called Acoris Research, in Pune, India, about 140 km from its headquarters. With eight synthetic chemistry labs, an analytical lab, and a kilolab facility operating to the U.S. Food & Drug Administration's current Good Manufacturing Practice standards, Acoris is offering the kind of "hit to lead" research that drug firms traditionally did in-house and that other Indian players such as Dishman Group and Jubilant Organosys now offer as a service, Swadi says.

Although Swadi and his colleagues hope that research contracts will lead to manufacturing deals, he says Hikal elected to run Acoris as a separate corporate entity. "A lot of potential customers may already have manufacturing tie-ins to other contractors, and others are concerned about patent protection," he says. "We wanted to set up a firewall between contract research and manufacturing."

With about 100 employees, Acoris already has 10 projects under way with both large and start-up pharmaceutical companies. It also has a contract with Pittsburgh-based Plextronics to manufacture chemicals for organic light-emitting diodes.

Running two separate businesses reflects concerns among some U.S. and European drug companies about protection of intellectual property in India, Swadi acknowledges. Yet he points out that Hikal has had successes—including contracts with Pfizer, Bayer CropScience, and Alpharma—that should help build the contract research subsidiary.

"Getting Western business is about achieving a level of satisfaction and comfort," Swadi says. "Our track record with big pharma on the manufacturing side will lead us to contracts for Acoris. Our respect for intellectual property rights is tremendous."

According to Enrico Polastro, a consultant with Arthur D. Little in Brussels, Indian suppliers in general have been moving up the value chain. "They are going beyond simply supplying headcount and reactor capacity to also offering value-added services," he says. "You will notice that Indian companies' booths at CPhI have signs that are no longer about products but about a broad range of capabilities."

Hikal, a long-time player in agricultural chemicals, has been pushing to boost its pharmaceuticals business with U.S. and European clients, according to Polastro. He notes that the president of Acoris, R. Helmut Rupp, is a former research executive at Lonza.

Swadi says Acoris plans a second phase of building in Pune to increase both research and kilolab-manufacturing capacities. "Hopefully, the financial environment will improve by next year," he says. "Once we have the orders in hand, we will build phase two."

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!